Neuroscientists identify a CRF-neuron "switch" in the brain's BNST region that, when activated, allows for significantly faster unlearning of fear responses.

HELUS Pharma has rebranded and moved to Nasdaq, signaling a shift toward late-stage clinical development and commercial focus ...

A weeklong, high-intensity version of TMS may work nearly as well as the standard six-week treatment for depression. In a UCLA study, patients who received five sessions a day for five days ...

Clinical trials are showing that DMT — the psychedelic compound in ayahuasca — can produce rapid antidepressant effects in a ...

A novel, non-hallucinogenic, experimental drug shows statistically significant, rapid, and durable improvement in PTSD symptom severity in a phase 2 trial.

Alkermes CEO Richard Pops is retiring this summer, ending a 35-year run at the top of the neuroscience company. Blair Jackson ...

A behavioral neurologist is seeing more patients whose carefully curated brain-health supplement stacks may be doing the opposite of what they intended — and the science behind why is something the ...